Clinical Scorecard: Alterations in GILZ/c-Rel/RACK1 Signaling Compromise Epithelial Barrier Function in Inflammatory Bowel Disease
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis
Key Mechanisms
Downregulation of RACK1 linked to decreased GILZ expression and NF-κB/c-Rel signaling, leading to SRC activation, reduced E-cadherin, and impaired epithelial barrier integrity
Target Population
Patients with IBD, particularly those with ulcerative colitis and low or no response to glucocorticoid treatment
Care Setting
Gastroenterology clinics and research settings focusing on IBD management and therapy development
Key Highlights
RACK1 expression is significantly decreased in IBD, especially ulcerative colitis, correlating with reduced GILZ protein levels.
Dexamethasone restores RACK1 expression via glucocorticoid receptor independently of c-Rel/GILZ, supporting its therapeutic role.
Guideline-Based Recommendations
Diagnosis
Assess epithelial barrier integrity and inflammatory markers in IBD patients.
Consider molecular analysis of RACK1 and GILZ expression in research or specialized diagnostic settings.
Management
Use glucocorticoids such as dexamethasone as first-line therapy to reduce inflammation and restore RACK1 expression.
Investigate alternative therapies targeting the GILZ/c-Rel/RACK1/SRC/E-cadherin pathway for patients with glucocorticoid resistance.
Monitoring & Follow-up
Monitor clinical response to glucocorticoids and epithelial barrier function.
Evaluate inflammatory cytokine levels (e.g., TNF-α, IL-1β, IL-6) as markers of disease activity and treatment efficacy.
Risks
Be aware of systemic side effects associated with glucocorticoid therapy.
Consider potential glucocorticoid resistance linked to alterations in GILZ/c-Rel/RACK1 signaling.
Patient & Prescribing Data
IBD patients, including those with ulcerative colitis and Crohn’s disease
Dexamethasone effectively restores RACK1 expression and improves epithelial barrier integrity via glucocorticoid receptor activation, even in c-Rel/GILZ-independent pathways, supporting its use as first-line therapy.
Clinical Best Practices
Incorporate glucocorticoid therapy early in IBD management to target inflammation and epithelial barrier restoration.
Consider molecular profiling of RACK1 and GILZ expression to identify patients who may benefit from targeted therapies.
Monitor for glucocorticoid resistance and explore alternative treatments targeting the RACK1/SRC/E-cadherin axis.
Address inflammatory cytokine levels to reduce epithelial barrier disruption and disease progression.
by Erica Buoso, Mirco Masi, Roberta Valeria Limosani, Francesca Fagiani, Chiara Oliviero, Giorgia Colombo, Luigi Cari, Marco Gentili, Eleonora Lusenti, Lucrezia Rosati, Federica Pisati, Alessandra Pasini, Marco Vincenzo Lenti, Antonio Di Sabatino, Claire Louise Mobbs, Stefan Przyborski, Simona Ronchetti, Cristina Travelli, Marco Racchi
